Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 11 09 2018
revised: 09 10 2018
accepted: 29 10 2018
pubmed: 16 11 2018
medline: 17 4 2019
entrez: 16 11 2018
Statut: ppublish

Résumé

Relatively little is known about factors that may lead to the development of a substance use disorder (SUD), across a range of drug classes. This study aimed to identify factors that predict the likelihood of transition from use to SUD and the speed with which this may occur at the population level, with a focus on the impact of pre-existing mental disorders. Data were collected as part of the 2007 Australian National Survey of Mental Health and Wellbeing, a nationally representative survey of 8841 Australian adults. A series of discrete time survival analyses were undertaken on data pertaining to the age of onset of use and symptoms of use disorder, for alcohol, cannabis, sedatives, stimulants, and opioids, as well as the impact of pre-existing mood and anxiety disorders on the likelihood of developing a SUD. Lifetime cumulative probability estimates indicated that 50.4% of stimulant, 46.6% of opioid, 39% of sedative, 37.5% of alcohol, and 34.1% of cannabis users would develop a SUD on those substances, within an estimated 14, 12, 8, 30, and 23 years after onset respectively. Pre-existing mental disorders were significantly associated with increased risk of developing a SUD for alcohol, cannabis and stimulant use disorder. The relative speed associated with the transition from use to SUD emphasizes the narrow window of time available to intervene, underscoring the urgency of early identification of mental health conditions and the timely provision of appropriate evidence-based interventions, which could potentially prevent the development of secondary SUDs.

Sections du résumé

BACKGROUND
Relatively little is known about factors that may lead to the development of a substance use disorder (SUD), across a range of drug classes. This study aimed to identify factors that predict the likelihood of transition from use to SUD and the speed with which this may occur at the population level, with a focus on the impact of pre-existing mental disorders.
METHODS
Data were collected as part of the 2007 Australian National Survey of Mental Health and Wellbeing, a nationally representative survey of 8841 Australian adults. A series of discrete time survival analyses were undertaken on data pertaining to the age of onset of use and symptoms of use disorder, for alcohol, cannabis, sedatives, stimulants, and opioids, as well as the impact of pre-existing mood and anxiety disorders on the likelihood of developing a SUD.
RESULTS
Lifetime cumulative probability estimates indicated that 50.4% of stimulant, 46.6% of opioid, 39% of sedative, 37.5% of alcohol, and 34.1% of cannabis users would develop a SUD on those substances, within an estimated 14, 12, 8, 30, and 23 years after onset respectively. Pre-existing mental disorders were significantly associated with increased risk of developing a SUD for alcohol, cannabis and stimulant use disorder.
CONCLUSION
The relative speed associated with the transition from use to SUD emphasizes the narrow window of time available to intervene, underscoring the urgency of early identification of mental health conditions and the timely provision of appropriate evidence-based interventions, which could potentially prevent the development of secondary SUDs.

Identifiants

pubmed: 30439610
pii: S0376-8716(18)30531-3
doi: 10.1016/j.drugalcdep.2018.10.010
pii:
doi:

Substances chimiques

Central Nervous System Stimulants 0
Hypnotics and Sedatives 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

136-142

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Christina Marel (C)

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia; NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, NSW 2052, Sydney, Australia. Electronic address: c.marel@unsw.edu.au.

Matthew Sunderland (M)

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia; NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, NSW 2052, Sydney, Australia.

Katherine L Mills (KL)

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia; NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, NSW 2052, Sydney, Australia.

Tim Slade (T)

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia; NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, NSW 2052, Sydney, Australia.

Maree Teesson (M)

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia; NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, NSW 2052, Sydney, Australia.

Cath Chapman (C)

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia; NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, NSW 2052, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH